ATE432955T1 - Polyglutamat-aminosäure-konjugate und verfahren - Google Patents

Polyglutamat-aminosäure-konjugate und verfahren

Info

Publication number
ATE432955T1
ATE432955T1 AT06838728T AT06838728T ATE432955T1 AT E432955 T1 ATE432955 T1 AT E432955T1 AT 06838728 T AT06838728 T AT 06838728T AT 06838728 T AT06838728 T AT 06838728T AT E432955 T1 ATE432955 T1 AT E432955T1
Authority
AT
Austria
Prior art keywords
polyglutamat
methods
amino acid
acid conjugates
biomolecule
Prior art date
Application number
AT06838728T
Other languages
English (en)
Inventor
Lei Yu
Gang Zhao
Sang Van
Sanjib Kumar Das
Zhongling Feng
Xiaoli Fu
Xinghe Wang
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Application granted granted Critical
Publication of ATE432955T1 publication Critical patent/ATE432955T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/48—Polymers modified by chemical after-treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/146—Peptides, e.g. proteins the peptide being a polyamino acid, e.g. poly-lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyamides (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT06838728T 2005-12-05 2006-12-01 Polyglutamat-aminosäure-konjugate und verfahren ATE432955T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74229105P 2005-12-05 2005-12-05
US75791706P 2006-01-10 2006-01-10
US79073506P 2006-04-10 2006-04-10
PCT/US2006/045915 WO2007067417A1 (en) 2005-12-05 2006-12-01 Polyglutamate-amino acid conjugates and methods

Publications (1)

Publication Number Publication Date
ATE432955T1 true ATE432955T1 (de) 2009-06-15

Family

ID=37909775

Family Applications (3)

Application Number Title Priority Date Filing Date
AT10004160T ATE544802T1 (de) 2005-12-05 2006-12-01 Polyglutamat-aminosäure-konjugate und verfahren
AT06838728T ATE432955T1 (de) 2005-12-05 2006-12-01 Polyglutamat-aminosäure-konjugate und verfahren
AT09004686T ATE465205T1 (de) 2005-12-05 2006-12-01 Polyglutamat-aminosäure-konjugate und verfahren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT10004160T ATE544802T1 (de) 2005-12-05 2006-12-01 Polyglutamat-aminosäure-konjugate und verfahren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT09004686T ATE465205T1 (de) 2005-12-05 2006-12-01 Polyglutamat-aminosäure-konjugate und verfahren

Country Status (15)

Country Link
US (2) US20070128118A1 (de)
EP (4) EP2325232A1 (de)
JP (1) JP5237821B2 (de)
KR (1) KR20080074207A (de)
CN (2) CN102125695B (de)
AT (3) ATE544802T1 (de)
AU (1) AU2006322254B2 (de)
BR (1) BRPI0619436A2 (de)
CA (1) CA2631704A1 (de)
DE (2) DE602006013893D1 (de)
DK (2) DK2206736T3 (de)
ES (1) ES2395461T3 (de)
RU (1) RU2472812C2 (de)
TW (1) TW200804461A (de)
WO (1) WO2007067417A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
DE10244847A1 (de) * 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
JP5237821B2 (ja) 2005-12-05 2013-07-17 日東電工株式会社 ポリグルタミン酸−アミノ酸結合体および方法
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
EP2144631A2 (de) * 2007-04-10 2010-01-20 Nitto Denko Corporation Multifunktionale polyglutamat-wirkstoffträger
FR2915748B1 (fr) * 2007-05-03 2012-10-19 Flamel Tech Sa Acides polyglutamiques fonctionnalises par des groupes cationiques et des groupements hydrophobes et leurs applications, notamment therapeutiques
DK2155255T3 (da) * 2007-05-09 2013-09-02 Nitto Denko Corp Sammensætninger der omfatter en hydrofob forbindelse og et polyaminosyrekonjugat
JP2010528122A (ja) * 2007-05-09 2010-08-19 日東電工株式会社 白金薬剤と結合されたポリマー
EP2155253A2 (de) * 2007-05-09 2010-02-24 Nitto Denko Corporation Polyglutamatkonjugate und polyglutamat-aminosäure-konjugate mit mehreren wirkstoffen
JP2008305262A (ja) * 2007-06-08 2008-12-18 Konica Minolta Business Technologies Inc サーバ及びシンクライアント環境でのプリンタ紹介方法
KR20100122510A (ko) * 2008-03-06 2010-11-22 닛토덴코 가부시키가이샤 중합체 파클리탁셀 접합체 및 암 치료 방법
EP2151249A1 (de) * 2008-07-28 2010-02-10 Canon Kabushiki Kaisha PH-Indikator bestehend aus Polymer und Fluoreszenzfarbstoff
KR20110051214A (ko) * 2008-07-30 2011-05-17 닛토덴코 가부시키가이샤 약물 담체
JP5744723B2 (ja) * 2008-09-12 2015-07-08 日東電工株式会社 線維性疾患のイメージング剤
WO2010042638A2 (en) 2008-10-07 2010-04-15 Young Bok Lee Hpma - docetaxel or gemcitabine conjugates and uses therefore
WO2010045370A2 (en) * 2008-10-15 2010-04-22 Nitto Denko Corporation Method of preparing polyglutamate conjugates
CN104587484A (zh) 2009-10-13 2015-05-06 瑞沙恩医药公司 用于抗癌剂递送的聚合物系统
AU2011224374A1 (en) * 2010-03-11 2012-09-27 Nitto Denko Corporation Carbohydrate-polyamino acid-drug conjugates
WO2011147330A1 (zh) * 2010-05-27 2011-12-01 中国医学科学院药物研究所 双功能共缀物的化学合成及抗肿瘤与抗肿瘤转移作用
TWI449823B (zh) * 2010-10-04 2014-08-21 Far Eastern New Century Corp Superabsorbent antibacterial fiber and its use
AU2012239933B2 (en) * 2011-04-06 2017-01-05 Cedars-Sinai Medical Center Polymalic acid based nanoconjugates for imaging
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
CN102442996B (zh) * 2011-09-16 2014-09-24 中山大学附属第一医院 多胺类小分子显像剂、其生产方法及其应用
CN102391168B (zh) * 2011-09-16 2013-11-27 中山大学附属第一医院 对称性双功能偶联剂及其偶合分子显像剂
ES2677478T3 (es) 2012-04-12 2018-08-02 Nitto Denko Corporation Conjugados de copolímero
US9078926B2 (en) 2012-05-07 2015-07-14 Nitto Denko Corporation Polymer conjugates with a linker
WO2014085471A1 (en) * 2012-11-28 2014-06-05 Prognosdx Health, Inc. Acid-activated compositions for the treatment of cancers, methods of their use and methods of their preparation
US20190015350A1 (en) 2013-02-05 2019-01-17 Anp Technologies, Inc. Nanoparticles Containing a Taxane and their Use
CN105143244A (zh) * 2013-04-26 2015-12-09 日东电工株式会社 降低多聚阴离子聚合物偶联物中的内毒素
US9636411B2 (en) 2013-04-26 2017-05-02 Nitto Denko Corporation Large scale process for preparing poly (glutamyl-glutamate) conjugates
CN103724618B (zh) * 2013-12-03 2016-10-26 江南大学 一种光敏性γ-聚谷氨酸接枝共聚物胶束的制备方法
JPWO2015129901A1 (ja) * 2014-02-27 2017-03-30 株式会社セルシード アミノ酸誘導体蛍光ポリマー及びそれを利用した蛍光プローブ
CA2943733C (en) * 2014-04-07 2022-03-01 Nitto Denko Corporation Polymer-based hydrotropes for hydrophobic drug delivery
CN113304278A (zh) * 2014-12-26 2021-08-27 日本化药株式会社 喜树碱类高分子衍生物的药物制剂
US11708464B2 (en) 2017-05-27 2023-07-25 Ecovia Renewables Inc. Poly (amino acid) rheology modifier compositions and methods of use
WO2022120147A1 (en) * 2020-12-04 2022-06-09 The Methodist Hospital System Amino acid polymer-platinum anticancer drug conjugates
WO2022174171A1 (en) * 2021-02-15 2022-08-18 Anp Technologies, Inc. Pharmaceutical composition containing taxane nanoaggregates and use thereof

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA71763B (en) * 1970-04-13 1972-03-29 Lilly Industries Ltd Erythromycylamines via hydrazones
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
JPS60501759A (ja) * 1983-07-01 1985-10-17 バテル　メモリアル　インステイチユ−ト 生物分解性ポリペプチド及び薬剤の緩慢な放出のためのその使用
US5385738A (en) * 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
DE3581471D1 (de) 1984-10-19 1991-02-28 Battelle Memorial Institute Durch mikroorganismen abbaubares polypeptid und seine verwendung fuer die fortschreitende abgabe von medikamenten.
CS254355B1 (en) * 1985-04-10 1988-01-15 Vladimir Saudek Soluble and biodegradatable copolymeres activated for bond of biologicaly active substances
CH667874A5 (fr) * 1985-12-19 1988-11-15 Battelle Memorial Institute Polypeptide synthetique biodegradable et son utilisation pour la preparation de medicaments.
US6673347B1 (en) * 1986-04-30 2004-01-06 Gryphon Therapeutics Polypeptide and protein derivatives and process for their preparation
US5102652A (en) 1986-07-03 1992-04-07 Advanced Magnetics Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
IN165717B (de) * 1986-08-07 1989-12-23 Battelle Memorial Institute
JP2517760B2 (ja) * 1989-05-11 1996-07-24 新技術事業団 水溶性高分子化医薬製剤
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
EP0526503B1 (de) 1990-04-10 1997-06-04 Imarx Pharmaceutical Corp. Polymere und ihre verwendung als kontrastmittel bei der bilderzeugung mit magnetischer resonanz
US5660822A (en) * 1990-05-14 1997-08-26 University Of Medicine & Dentistry Of N.J. Polymers containing antifibrotic agents, compositions containing such polymers, and methods of preparation and use
US5219564A (en) * 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
US6517824B1 (en) * 1990-05-14 2003-02-11 University Of Medicine & Denistry Of New Jersey Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
US5372807A (en) * 1990-05-14 1994-12-13 University Of Medicine And Dentistry Of New Jersey Polymers containing antifibrotic agents, compositions containing such polymers, and methods of preparation and use
GB9013615D0 (en) 1990-06-19 1990-08-08 Wellcome Found Pharmaceutical compounds
US6762188B1 (en) * 1990-06-19 2004-07-13 Smithkline Beecham Corporation Pharmaceutically active benzoquinazoline compounds
DE4115789A1 (de) * 1991-05-10 1992-11-12 Schering Ag Makrocyclische polymer-komplexbildner, deren komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
JP2589431B2 (ja) 1991-05-13 1997-03-12 株式会社ディ・ディ・エス研究所 糖修飾ポリグルタミン酸誘導体及びその製造法
GB9120653D0 (en) 1991-09-27 1991-11-06 Procter & Gamble Dispensing agent
US5384333A (en) * 1992-03-17 1995-01-24 University Of Miami Biodegradable injectable drug delivery polymer
KR940003548U (ko) * 1992-08-14 1994-02-21 김형술 세탁물 건조기
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
FR2695563B1 (fr) * 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
US6004763A (en) 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
CA2155947C (en) * 1993-02-22 2007-08-21 Mark W. Grinstaff Methods for in vivo delivery of biologics and compositions useful therefor
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5548064A (en) * 1993-05-24 1996-08-20 Biotech Australia Pty Limited Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions
US5449720A (en) * 1993-05-24 1995-09-12 Biotech Australia Pty Limited Amplification of the VB12 uptake system using polymers
GB2282384B8 (en) * 1993-08-18 1997-09-04 Europ Economic Community Drug delivery agents incorporating mitomycin
US6441026B1 (en) * 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
US5980862A (en) 1995-06-02 1999-11-09 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
US6713045B1 (en) * 1995-06-02 2004-03-30 Research Corporation Technologies, Inc. Targeted magnetic resonance imaging agents for the detection of physiological processes
US5762909A (en) * 1995-08-31 1998-06-09 General Electric Company Tumor targeting with polymeric molecules having extended conformation
DE19548114C2 (de) * 1995-12-21 2000-04-27 Deutsches Krebsforsch Konjugat, umfassend einen Wirkstoff, ein Polypeptid und einen Polyether
PL189698B1 (pl) 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US6030941A (en) * 1996-05-01 2000-02-29 Avi Biopharma, Inc. Polymer composition for delivering substances in living organisms
US5929198A (en) 1996-07-16 1999-07-27 Nalco Chemical Company Biodegradable poly (amino acid)s, derivatized amino acid polymers and methods for making same
US5900228A (en) * 1996-07-31 1999-05-04 California Institute Of Technology Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye
AU7124598A (en) 1997-04-18 1998-11-13 Access Pharmaceuticals, Inc. Polymer-platinum compounds
US5965118A (en) 1997-04-18 1999-10-12 Access Pharmaceuticals, Inc. Polymer-platinum compounds
US6251866B1 (en) * 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
US6229009B1 (en) * 1997-08-29 2001-05-08 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Polycarboxylic based cross-linked copolymers
US6528061B1 (en) * 1997-09-04 2003-03-04 Pasteur Institut Immunogenic polypeptides that mimic a surface polysaccharide antigen of a pathogenic microorganism, method for obtaining the same, and their use in vaccine compositions
JP3390965B2 (ja) * 1997-09-12 2003-03-31 理化学研究所 糖結合スフィンゴシンを含有するポリマー化合物
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US20040170563A1 (en) 1997-10-27 2004-09-02 Meade Thomas J. Magnetic resonance imaging agents for the delivery of therapeutic agents
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
AU2795499A (en) 1998-02-26 1999-09-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Conjugated suramin or derivatives thereof with peg, polyaspartate or polyglutamate for cancer treatment
US5981564A (en) 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
US20030124143A1 (en) * 1998-08-31 2003-07-03 Armelle Phalipon Methods for selecting immunogenic polypeptides
US6143817A (en) 1998-10-07 2000-11-07 National Starch & Chemical Co. Use of derivatives of polyamino acids as emulsifiers stabilizers in aqueous free radical emulsion polymerization
WO2000038735A1 (fr) * 1998-12-24 2000-07-06 Kyowa Hakko Kogyo Co., Ltd. Preparation pharmaceutique
EP1031354A3 (de) 1999-01-19 2003-02-05 Rohm And Haas Company Polymere MRI Kontrastmittel
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20010041189A1 (en) * 1999-04-13 2001-11-15 Jingya Xu Poly(dipeptide) as a drug carrier
US20040121954A1 (en) * 1999-04-13 2004-06-24 Xu Wuhan Jingya Poly(dipeptide) as a drug carrier
WO2000063409A1 (en) 1999-04-21 2000-10-26 Massachusetts Institute Of Technology Endosomolytic agents and cell delivery systems
US7005123B1 (en) 1999-06-17 2006-02-28 Universiteit Gent Functional poly-α-amino-acid derivatives useful for the modification of biologically active materials and their application
US6326021B1 (en) 1999-06-18 2001-12-04 The Ohio State University Research Foundation Biocompatible polymeric delivery systems having functional groups attached to the surface thereof
US20030054977A1 (en) * 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
MXPA02003719A (es) 1999-10-12 2002-08-30 Cell Therapeutics Inc Fabricacion de congujados de poliglutamato-agente terapeutico.
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US6235264B1 (en) * 1999-12-01 2001-05-22 General Electric Company Medical imaging method for characterizing tumor angiogenesis using polymeric contrast agents
US6685915B2 (en) 1999-12-01 2004-02-03 General Electric Company Extended-linear polymeric contrast agents, and synthesizing methods, for medical imaging
US7166733B2 (en) 2000-01-04 2007-01-23 Access Pharmaceuticals, Inc. O,O'-Amidomalonate and N,O-Amidomalonate platinum complexes
CA2396702C (en) 2000-01-04 2010-03-23 Access Pharmaceuticals, Inc. N,o-amidomalonate platinum complexes
US20020183243A1 (en) 2000-03-17 2002-12-05 Cell Therapeutics, Inc. Polyglutamic acid-camptothecin conjugates and methods of preparation
KR20020082888A (ko) * 2000-03-17 2002-10-31 쎌세러퓨틱스,인코포레이티드 폴리글루탐산-캄프토테신 컨주게이트 및 제조 방법
US20020077290A1 (en) * 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
WO2001074399A1 (en) * 2000-03-30 2001-10-11 Ajinomoto Co., Inc. Drugs retained in target tissue over long time
JP2001288097A (ja) 2000-04-07 2001-10-16 Pg-Txl Co Lp 水溶性パクリタキセル誘導体
AU2001275525B2 (en) 2000-06-14 2007-04-26 Medarex, Inc. Tripeptide prodrug compounds
GB0018240D0 (en) 2000-07-25 2000-09-13 Pharmacia & Upjohn Spa Polymeric conjugates of antitumor agents
WO2002026241A1 (en) 2000-09-26 2002-04-04 Center For Advanced Science And Technology Incubation, Ltd. Polymeric micelle containing cisplatin enclosed therein and use thereof
AU2001295073A1 (en) * 2000-09-29 2002-04-08 The Regents Of The University Of California Dendrimeric support or carrier macromolecule
US6497901B1 (en) 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds
US7070797B2 (en) * 2000-11-07 2006-07-04 Dana Farber Cancer Institute, Inc. Method of treating hematologic tumors and cancers
US6916492B2 (en) 2001-03-30 2005-07-12 Council Of Scientific & Industrial Research Natural nontoxic multicolor fluorescent protein dye from a marine invertebrate, compositions containing the said dye and its uses
CA2444483A1 (en) 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Diagnostic imaging compositions, their methods of synthesis and use
WO2002087497A2 (en) 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
ES2343679T3 (es) * 2001-06-20 2010-08-06 Nippon Kayaku Kabushiki Kaisha Copolimeros de bloques con bajo contenido de impurezas; vehiculo polimerico; preparaciones farmaceuticas en forma polimerica y procedimiento para la preparacion del mismo.
US20040043030A1 (en) * 2001-07-31 2004-03-04 Immunomedics, Inc. Polymeric delivery systems
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
US20030109432A1 (en) * 2001-12-10 2003-06-12 Zuo William W. Anticancer polypeptide-metal complexes and compositions, methods of making, and methods of using same
US7262164B2 (en) * 2001-11-09 2007-08-28 Enzon, Inc. Polymeric thiol-linked prodrugs employing benzyl elimination systems
US7261875B2 (en) 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
CN1252130C (zh) 2002-04-01 2006-04-19 北京键凯科技有限公司 亲水性聚合物与丹参酮类药物的结合物以及包含该结合物的药物组合物
US6939538B2 (en) 2002-04-11 2005-09-06 Biomedical Research Models, Inc. Extended release analgesic for pain control
JP2004018494A (ja) 2002-06-19 2004-01-22 Japan Science & Technology Corp ブロック共重合体−薬剤複合体の製造法
US20040047835A1 (en) * 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
FR2844514B1 (fr) * 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
CA2502870C (en) * 2002-10-31 2011-07-26 Nippon Kayaku Kabushiki Kaisha High-molecular weight derivatives of camptothecins
US20070020272A1 (en) 2003-04-30 2007-01-25 Tayyaba Hasan Indirectly linked photosensitizer immunoconjugates, processes for the production thereof and methods of use thereof
FR2855521B1 (fr) * 2003-05-28 2005-08-05 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques.
WO2004108667A2 (en) * 2003-05-30 2004-12-16 Centocor, Inc. Formation of novel erythropoietin conjugates using transglutaminase
US6855695B2 (en) * 2003-06-13 2005-02-15 Vion Pharmaceuticals, Inc. Water-soluble SHPs as novel alkylating agents
US20050187147A1 (en) * 2003-09-22 2005-08-25 Newman Michael J. Compositions and methods for increasing drug efficiency
US20050118718A1 (en) * 2003-09-22 2005-06-02 University Of Utah Research Foundation Stabilization and controlled delivery of ionic biopharmaceuticals
CA2548457C (en) * 2003-12-10 2010-08-24 Toudai Tlo, Ltd. Coordination complex of diaminocyclohexaneplatinum(ii) with block copolymer containing poly(carboxylic acid) segment and antitumor agent comprising the same
WO2005063304A2 (en) * 2003-12-24 2005-07-14 Board Of Regents, The University Of Texas_System Poly (l-glutamic acid) paramagnetic material complex and use as a biodegradable mri contrast agent
WO2005079861A2 (en) 2004-02-13 2005-09-01 Safeway Investments Ltd. Polymeric water soluble prodrugs
JP2007526322A (ja) 2004-03-02 2007-09-13 マサチューセッツ インスティテュート オブ テクノロジー ナノセル薬物送達系
US7317070B1 (en) * 2004-03-12 2008-01-08 Sigma-Aldrich Co. Process for the preparation of polyamino acids
CA2562283A1 (en) 2004-04-09 2005-11-24 3M Innovative Properties Company Methods, compositions, and preparations for delivery of immune response modifiers
KR20050104152A (ko) * 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
US20050271585A1 (en) 2004-06-07 2005-12-08 General Electric Company Extended conjugated polymers
US20050276783A1 (en) 2004-06-10 2005-12-15 Ernest Giralt Lledo Polypeptides with the capacity to entrap drugs and release them in a controlled way
CN100475837C (zh) 2004-06-11 2009-04-08 北京键凯科技有限公司 多叉分支的聚乙二醇-氨基酸寡肽及其活性衍生物和药物结合物
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
WO2006041613A2 (en) 2004-10-05 2006-04-20 Nanomega Medical Corporation Nanoparticles for targeting hepatoma cells
CA2583389A1 (en) 2004-10-07 2006-04-20 Emory University Multifunctional nanoparticles conjugates and their use
DE602005024437D1 (de) 2004-12-03 2010-12-09 Univ Utah Res Found Mrt-geführte photodynamische therapie gegen krebs
JP5237821B2 (ja) 2005-12-05 2013-07-17 日東電工株式会社 ポリグルタミン酸−アミノ酸結合体および方法
US20080051603A1 (en) 2006-06-15 2008-02-28 Cell Therapeutics, Inc. Process for the preparation of poly-alpha-glutamic acid and derivatives thereof
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
EP2144631A2 (de) 2007-04-10 2010-01-20 Nitto Denko Corporation Multifunktionale polyglutamat-wirkstoffträger
JP2010528122A (ja) 2007-05-09 2010-08-19 日東電工株式会社 白金薬剤と結合されたポリマー
EP2155253A2 (de) 2007-05-09 2010-02-24 Nitto Denko Corporation Polyglutamatkonjugate und polyglutamat-aminosäure-konjugate mit mehreren wirkstoffen
DK2155255T3 (da) 2007-05-09 2013-09-02 Nitto Denko Corp Sammensætninger der omfatter en hydrofob forbindelse og et polyaminosyrekonjugat
KR20100122510A (ko) 2008-03-06 2010-11-22 닛토덴코 가부시키가이샤 중합체 파클리탁셀 접합체 및 암 치료 방법
WO2009141823A2 (en) 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases
JP5744723B2 (ja) 2008-09-12 2015-07-08 日東電工株式会社 線維性疾患のイメージング剤
WO2010045370A2 (en) 2008-10-15 2010-04-22 Nitto Denko Corporation Method of preparing polyglutamate conjugates
CA2782410A1 (en) * 2009-12-16 2011-06-23 Nitto Denko Corporation Controlled synthesis of polyglutamic acid
AU2011224374A1 (en) 2010-03-11 2012-09-27 Nitto Denko Corporation Carbohydrate-polyamino acid-drug conjugates
FR2957692B1 (fr) 2010-03-17 2012-06-08 Delphi Tech Inc Dispositif de commande a commutateur rotatif retro-eclaire par un guide de lumiere
US20120052015A1 (en) * 2010-08-26 2012-03-01 Nitto Denko Corporation End-capped polymers

Also Published As

Publication number Publication date
US20170119889A1 (en) 2017-05-04
EP1969031B1 (de) 2009-06-03
ATE544802T1 (de) 2012-02-15
AU2006322254B2 (en) 2012-08-02
DE602006007177D1 (de) 2009-07-16
BRPI0619436A2 (pt) 2011-10-04
HK1124627A1 (en) 2009-07-17
ATE465205T1 (de) 2010-05-15
CN101321806B (zh) 2011-01-26
HK1135421A1 (en) 2010-06-04
JP5237821B2 (ja) 2013-07-17
DK1969031T3 (da) 2009-09-14
RU2472812C2 (ru) 2013-01-20
EP1969031A1 (de) 2008-09-17
TW200804461A (en) 2008-01-16
DK2206736T3 (da) 2012-04-23
DE602006013893D1 (de) 2010-06-02
US20070128118A1 (en) 2007-06-07
US9855338B2 (en) 2018-01-02
CA2631704A1 (en) 2007-06-14
EP2077290A1 (de) 2009-07-08
CN102125695A (zh) 2011-07-20
HK1146075A1 (en) 2011-05-13
EP2206736A1 (de) 2010-07-14
EP2325232A1 (de) 2011-05-25
CN101321806A (zh) 2008-12-10
WO2007067417A1 (en) 2007-06-14
ES2395461T3 (es) 2013-02-12
EP2206736B1 (de) 2012-02-08
EP2077290B1 (de) 2010-04-21
RU2008120699A (ru) 2010-01-20
JP2009518511A (ja) 2009-05-07
AU2006322254A1 (en) 2007-06-14
KR20080074207A (ko) 2008-08-12
CN102125695B (zh) 2014-02-19

Similar Documents

Publication Publication Date Title
ATE544802T1 (de) Polyglutamat-aminosäure-konjugate und verfahren
WO2008094834A3 (en) Multi-functional drug carriers
WO2008124735A3 (en) Multi-functional polyglutamate drug carriers
CY1115715T1 (el) Διαλυτοποιηση και στοχευομενη χορηγηση δραστικων ουσιων με αυτο-οργανουμενα αμφιφιλα πολυμερη
WO2008141110A3 (en) Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs
FI20051203L (fi) Alifaattisiin biohajoaviin välikeosiin perustuvat vapautettavat polymeerikonjugaatit
DE602007014087D1 (de) Blockcopolymer für wirkstoffkonjugate und deren pharmazeutische zusammensetzungen
BRPI0815261A2 (pt) "sistema anastomótico vascular absorvível"
EA200301250A1 (ru) Фармацевтические композиции, содержащие слаборастворимые и/или чувствительные к кислотам лекарственные средства и нейтрализованные кислотные полимеры
WO2007127440A3 (en) Heterofunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof
PL374523A1 (pl) Koniugaty pochodna kalicheamycyny-nośnik
WO2008005371A3 (en) Poly(orthoester) polymers, and methods of making and using same
CY1108685T1 (el) Συστημα απελευθερωσης φαρμακου που πηζει in-situ
CY1111389T1 (el) Φαρμακευτικες ενωσεις που περιεχουν ιματινιμπη και ενα επιβραδυντικο εκλυσης
MX2009011247A (es) Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
DK1793994T3 (da) Polymælkesyreblæst film og fremgangsmåde til fremstilling deraf
PT1891962E (pt) Sistema de administração à base de glutationa
DK1543063T3 (da) Medikament levering
ATE326968T1 (de) Pharmazeutische zusammensetzung enthaltend tenatoprazol und einen entzündungshemmer
NO20082848L (no) Farmasoytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre
ATE540996T1 (de) Polymerbasierter serumalbumin-ersatzstoff
ATE491475T1 (de) Konjugate enthaltend gm-csf und ein polymer
ATE549016T1 (de) Pharmazeutische zusammensetzungen mit verbesserten auflöseprofilen für schwerlösliche wirkstoffe
DE60320591D1 (de) Tumorselektives und biologisch abbaubares polyphosphazen-platin(ii)-konjugat-antitumormittel und verfahren zu dessen herstellung
DE602006019302D1 (de) Organosilicium-polymer und verfahren zu dessen herstellung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties